Linkage disequilibrium and association with methamphetamine dependence/psychosis of mu-opioid receptor gene polymorphisms

• Published in: The pharmacogenomics journal Vol. 6; no. 3; pp. 179 - 188
• Main Authors: Ide, S, Kobayashi, H, Ujike, H, Ozaki, N, Sekine, Y, Inada, T, Harano, M, Komiyama, T, Yamada, M, Iyo, M, Iwata, N, Tanaka, K, Shen, H, Iwahashi, K, Itokawa, M, Minami, M, Satoh, M, Ikeda, K, Sora, I
• Format: Journal Article
• Language: English
• Published: United States Nature Publishing Group 01.05.2006
• Subjects: Adult; Amphetamine-Related Disorders - genetics; Case-Control Studies; Drug abuse; Drug addiction; Female; Gene frequency; Gene polymorphism; Humans; Linkage Disequilibrium; Male; Methamphetamine; Methamphetamine - adverse effects; Narcotics; Opioid receptors; Polymorphism, Genetic; Psychosis; Psychotic Disorders - genetics; Receptors, Opioid, mu - genetics; Single-nucleotide polymorphism
• ISSN: 1470-269X; 1473-1150
• DOI: 10.1038/sj.tpj.6500355

Several studies indicate that the mu-opioid receptor plays a role in addiction not only to opiate drugs but also to alcohol and non-opiate addictive drugs. Our studies aim to reveal the associations between gene polymorphisms and methamphetamine (MAP) dependence/psychosis. We newly identified several polymorphisms and four substantial linkage disequilibrium (LD) blocks in the mu-opioid receptor (OPRM1) gene. We found significant differences in both genotype and allele frequencies of the single-nucleotide polymorphism (SNP) IVS2+G691C between control (n=232) and MAP-dependent/psychotic patients (n=128). There was also a significant association between IVS2+G691C and patients with transient psychosis. These results suggest that the OPRM1 gene variations may be a factor in development and prognosis of MAP psychosis.